Rigel (RIGL) CFO granted 20,636 restricted stock units in equity award

Rhea-AI Filing Summary

Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported an equity award of company stock. He acquired 20,636 shares of common stock through a grant of restricted stock units at a stated price of $0.00 per share. Following this grant, he directly holds 76,337 common shares.

The award vests over time rather than all at once. The restricted stock units are scheduled to vest quarterly over three years, with the first quarterly vesting date on March 31, 2026. As each portion vests, the corresponding shares of common stock will be delivered to him.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schorno Dean L

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	20,636	$0.00	--

Holdings After Transaction: Common Stock — 76,337 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schorno Dean L

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		20,636(1)	A	$0	76,337	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

	/s/ Raymond Furey (Attorney-in-Fact)	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rigel Pharmaceuticals (RIGL) report for Dean L. Schorno?

Rigel Pharmaceuticals reported that EVP & Chief Financial Officer Dean L. Schorno received a grant of 20,636 restricted stock units of common stock. These units represent share-based compensation and are awarded at a stated price of $0.00 per share, rather than being purchased in the open market.

How many Rigel (RIGL) shares does Dean L. Schorno hold after this Form 4 transaction?

After the equity award, Dean L. Schorno directly holds 76,337 shares of Rigel common stock. This total reflects the addition of 20,636 restricted stock units granted as part of his compensation package, which will convert into shares as they vest over the three-year schedule.

What are the vesting terms of Dean L. Schorno’s Rigel (RIGL) restricted stock units?

The 20,636 restricted stock units granted to Dean L. Schorno vest quarterly over three years. The first quarterly vesting occurs on March 31, 2026. After each quarterly vest, the corresponding portion of units converts into shares of common stock deliverable to him.

Did Dean L. Schorno buy Rigel (RIGL) shares on the open market in this Form 4?

No, the Form 4 shows an acquisition through a grant, not an open-market purchase. The transaction code is “A,” indicating a grant, award, or other acquisition of 20,636 restricted stock units as compensation, with a reported price per share of $0.00.

What does the transaction code “A” mean in the Rigel (RIGL) Form 4 for Dean L. Schorno?

Transaction code “A” on the Form 4 indicates a grant, award, or other acquisition of securities. In this case, Dean L. Schorno received 20,636 restricted stock units of Rigel common stock as an equity award rather than through a market transaction.